Curis (CRIS) Tops Q4 EPS by 3c, Revenues Beat

Curis (NASDAQ: CRIS) reported Q4 EPS of ($0.18), $0.03 better than the analyst estimate of ($0.21). Revenue for the quarter came in at $2.76 million versus the consensus estimate of $2.6 million.

"2018 was a pivotal year for Curis as we transitioned from a company broadly engaged in discovery research and pipeline expansion into a company singularly focused on clinical execution," said James Dentzer, President and Chief Executive Officer of Curis. "We now have three novel programs in the clinic, all potential blockbusters and all with significant data catalysts expected in 2019."

Dentzer continued, "With our recently announced agreement with Oberland Capital, we secured the financial flexibility needed to ensure we can continue to move forward aggressively in our clinical execution on all three programs and produce the data readouts everyone is so excited to see.

"As we move through 2019, we are focused on the development of first-in-class and best-in-class precision medicines that we hope will transform the lives of patients," he concluded.

For earnings history and earnings-related data on Curis (CRIS) click here.

You May Also Be Interested In

• Two Harbors rejects UWM Holdings lawsuit amid pending CrossCountry deal
• Kyverna Therapeutics, Inc. (KYTX) Tops Q2 EPS by 45c
• Black Rock Coffee Bar, Inc. (BRCB) Misses Q2 EPS by 1c